Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000563385 | SCV000675664 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-07-29 | criteria provided, single submitter | clinical testing | The p.H1769Y variant (also known as c.5305C>T), located in coding exon 41 of the TSC2 gene, results from a C to T substitution at nucleotide position 5305. The histidine at codon 1769 is replaced by tyrosine, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV000644196 | SCV000765886 | benign | Tuberous sclerosis 2 | 2024-01-10 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000644196 | SCV002040279 | likely benign | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000644196 | SCV003821627 | uncertain significance | Tuberous sclerosis 2 | 2022-03-26 | criteria provided, single submitter | clinical testing |